Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus

[Display omitted] •Synthesis and characterization of 20 isoxazolyl-sulfonamides are reported.•The compounds were active against T. cruzi, L. amazonensis, and HSV-1.•Druglikeness evaluation showed potential for further pre-clinical development. In this study we report the synthesis, characterization,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic & medicinal chemistry letters 2018-11, Vol.28 (20), p.3381-3384
Hauptverfasser: da Rosa, Rafael, Zimmermann, Lara Almida, de Moraes, Milene Höehr, Schneider, Naira Fernanda Zanchett, Schappo, Alice Duarte, Simões, Claudia Maria de Oliveira, Steindel, Mario, Schenkel, Eloir Paulo, Bernardes, Lílian Sibelle Campos
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[Display omitted] •Synthesis and characterization of 20 isoxazolyl-sulfonamides are reported.•The compounds were active against T. cruzi, L. amazonensis, and HSV-1.•Druglikeness evaluation showed potential for further pre-clinical development. In this study we report the synthesis, characterization, biological evaluation, and druglikeness assessment of a series of 20 novel isoxazolyl-sulfonamides, obtained by a four-step synthetic route. The compounds had their activity against Trypanosoma cruzi, Leishmania amazonensis, Herpes Simplex Virus type 1 and cytotoxicity evaluated in phenotypic assays. All compounds have drug-like properties, showed low cytotoxicity and were promising regarding all other biological activities reported herein, especially the inhibitory activity against T. cruzi. The compounds 8 and 16 showed significant potency and selectivity against T. cruzi (GI50 = 14.3 µM, SI > 34.8 and GI50 = 11.6 µM, SI = 29.1, respectively). These values, close to the values of the reference drug benznidazole (GI50 = 10.2 µM), suggest that compounds 8 and 16 represent promising candidates for further pre-clinical development targeting Chagas disease.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2018.08.040